None
Quote | Adynxx Inc (NYSE:ADYX)
Last: | $ |
---|---|
Change Percent: | 4.88% |
Open: | $1.16 |
Close: | $1.29 |
High: | $1.29 |
Low: | $1.16 |
Volume: | 1,200 |
Last Trade Date Time: | 02/12/2020 04:42:05 pm |
News | Adynxx Inc (NYSE:ADYX)
Adynxx ( OTC:ADYX ): Q3 GAAP EPS of -$0.33. More news on: Adynxx, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced fi...
Message Board Posts | Adynxx Inc (NYSE:ADYX)
Subject | By | Source | When |
---|---|---|---|
With news, this could be an $11 stock!!!! | Termite7 | investorshub | 01/06/2021 12:51:39 PM |
$ADYX FLOAT ONLY 600K FLYING$ FAST!!! All buys | Soulman856 | investorshub | 06/30/2020 3:20:27 PM |
Another reverse split. How did the last | ARO | investorshub | 08/23/2019 11:27:29 AM |
ADYX delisted from NASDAQ. | 420man | investorshub | 06/13/2019 12:06:29 AM |
znewcar1: Why do you say that? Explosion in a good or bad way? Bearish two days under new ticker ADY | znewcar1 | investorshangout | 05/08/2019 3:07:23 AM |
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced fi...
SAN FRANCISCO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced th...
SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced fi...